Home Other Building Blocks 923564-51-6
923564-51-6,MFCD12756219
Catalog No.:AA0036UO

923564-51-6 | ABT-263

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$29.00   $21.00
- +
5mg
≥98%
in stock  
$85.00   $59.00
- +
10mg
98%
in stock  
$132.00   $93.00
- +
25mg
98%
in stock  
$183.00   $128.00
- +
50mg
98%
in stock  
$256.00   $179.00
- +
100mg
98%
in stock  
$382.00   $267.00
- +
250mg
95%
in stock  
$477.00   $334.00
- +
1g
95%
in stock  
$1,477.00   $1,034.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA0036UO
Chemical Name:
ABT-263
CAS Number:
923564-51-6
Molecular Formula:
C47H55ClF3N5O6S3
Molecular Weight:
974.6127
MDL Number:
MFCD12756219
SMILES:
Clc1ccc(cc1)C1=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(c(c2)S(=O)(=O)C(F)(F)F)N[C@@H](CSc2ccccc2)CCN2CCOCC2)CC(CC1)(C)C
Properties
Properties
 
Form:
Solid  
MP:
>122°C (dec.)  
Storage:
Light sensitive;Keep in dry area;2-8℃;  

Computed Properties
 
Complexity:
1800  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
65  
Hydrogen Bond Acceptor Count:
14  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
16  
XLogP3:
9.6  

Literature

Title: Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.

Journal: Toxicology in vitro : an international journal published in association with BIBRA 20180201

Title: Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.

Journal: Chemico-biological interactions 20160425

Title: Antioncogenic and Oncogenic Properties of Nrf2 in Arsenic-induced Carcinogenesis.

Journal: The Journal of biological chemistry 20151106

Title: Nrf2/p62 signaling in apoptosis resistance and its role in cadmium-induced carcinogenesis.

Journal: The Journal of biological chemistry 20141010

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

Journal: Biochemical pharmacology 20130401

Title: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Journal: Nature medicine 20130201

Title: Bax and Bcl-xL exert their regulation on different sites of the ceramide channel.

Journal: The Biochemical journal 20120701

Title: Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Journal: Cell death & disease 20120701

Title: In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution.

Journal: Cancer research 20120615

Title: Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

Journal: Blood 20120614

Title: Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120601

Title: Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.

Journal: Molecular cancer therapeutics 20120401

Title: ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.

Journal: Cancer chemotherapy and pharmacology 20120301

Title: WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.

Journal: Laboratory investigation; a journal of technical methods and pathology 20120301

Title: 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120301

Title: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210

Title: Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210

Title: From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210

Title: A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.

Journal: PloS one 20120101

Title: Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.

Journal: The Journal of pharmacology and experimental therapeutics 20111201

Title: The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

Journal: Molecular cancer therapeutics 20111201

Title: Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.

Journal: Biochemical pharmacology 20111101

Title: Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.

Journal: Cell death & disease 20111101

Title: Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.

Journal: Pathology 20111001

Title: Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.

Journal: Blood 20110811

Title: Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.

Journal: Experimental hematology 20110801

Title: Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.

Journal: Cancer research 20110701

Title: BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.

Journal: Blood 20110630

Title: Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

Title: The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.

Journal: Biochemical and biophysical research communications 20110506

Title: Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.

Journal: Journal of medicinal chemistry 20110324

Title: Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

Title: ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.

Journal: Oncology reports 20110301

Title: Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110301

Title: Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells.

Journal: PloS one 20110101

Title: Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

Journal: PloS one 20110101

Title: Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Journal: The Lancet. Oncology 20101201

Title: A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax).

Journal: Molecular cancer therapeutics 20101101

Title: Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.

Journal: Cancer biology & therapy 20101101

Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

Journal: Journal of medicinal chemistry 20101014

Title: The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.

Journal: Cancer chemotherapy and pharmacology 20101001

Title: Drugs targeting Bcl-2 family members as an emerging strategy in cancer.

Journal: Expert reviews in molecular medicine 20100908

Title: Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100815

Title: Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.

Journal: Molecular cancer therapeutics 20100301

Title: Aileron staples peptides.

Journal: Chemistry & biology 20090925

Title: Update on developmental therapeutics for acute lymphoblastic leukemia.

Journal: Current hematologic malignancy reports 20090701

Title: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

Journal: Cell death and differentiation 20090301

Title: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

Title: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.

Journal: Journal of cellular physiology 20090101

Title: Mimicking the BH3 domain to kill cancer cells.

Journal: Oncogene 20081201

Title: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Journal: Journal of medicinal chemistry 20081113

Title: ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.

Journal: Molecular cancer therapeutics 20081001

Title: Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.

Journal: Pediatric blood & cancer 20080601

Title: Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080601

Title: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Journal: Cancer research 20080501

Title: A matter of life and death.

Journal: Cancer cell 20020201

Title: An informatics approach identifying markers of chemosensitivity in human cancer cell lines.

Journal: Cancer research 20001101

Title: Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-1189.

Title: Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11(4):1026-1035.

Title: Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 923564-51-6
Tags:923564-51-6 Molecular Formula|923564-51-6 MDL|923564-51-6 SMILES|923564-51-6 ABT-263